UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Evolus, Inc. (NASDAQ:EOLS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Evolus, Inc. (NASDAQ:EOLS) by 6.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 115,052 shares of the company’s stock after buying an additional 6,821 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Evolus worth $1,270,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. KBC Group NV acquired a new position in shares of Evolus during the fourth quarter worth about $49,000. IFP Advisors Inc lifted its position in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after acquiring an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Activity at Evolus

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. This trade represents a 28.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the transaction, the chief financial officer now owns 173,583 shares in the company, valued at approximately $2,301,710.58. The trade was a 4.93% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,241 shares of company stock worth $1,048,666. Insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on EOLS shares. BTIG Research assumed coverage on Evolus in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $23.75.

Evolus Trading Down 3.9%

Evolus stock opened at $9.65 on Tuesday. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The firm has a market capitalization of $622.19 million, a PE ratio of -10.60 and a beta of 1.00. The business’s 50-day simple moving average is $10.34 and its 200-day simple moving average is $11.86. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.